2024-515219-23-00RecruitingPhase 1
MYELOFLUDATEP: Exploratory study evaluating the value of 18F-Fludarabine PET for the initial or relapsed assessment and therapeutic evaluation of patients with symptomatic multiple myeloma.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 15 Jul 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- First submitted
- 30 Sept 2024
- Start date
- 8 Nov 2024
- Lead sponsor
- Centre Hospitalier Universitaire De Nantes
- Diseases
- Multiple myeloma
- EU CT number
- 2024-515219-23-00
- EudraCT number
- 2018-002723-42
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 35
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier Regional D'Angers | Angers | France | Recruiting |
| Centre Hospitalier Régional et Universitaire de Brest | Brest | France | Recruiting |
| Centre Hospitalier Universitaire De Caen Normandie | Caen Cedex 9 | France | Recruiting |
| Centre Hospitalier Universitaire De Nantes | Nantes Cedex 1 | France | Recruiting |
| Centre Hospitalier Régional Universitaire de Tours | Tours | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.